Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of VARIVAX in Healthy Russian Individuals
NCT03843632Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 3 trial of varicella virus vaccine live in varicella (VZV), sponsored by Merck & Co.. Started Mar 2019; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT03843632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843632.